Payment overview · 2025
General Payments
$1,280.69
62 reported records · 15 companies
Healthcare provider profile · identity verified
Jean Robert Macenat, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · BRONX, NY · NPI 1104886860
Verified facts
What the public records show
CMS Open Payments records show Jean Robert Macenat, M.D received $1,280.69 in general payments during 2025 across 62 reported records.
ABBVIE INC. accounted for 15.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Linzess, Ozempic, Rybelsus, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Linzess by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xarelto by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $199.94 | 15.6% | 14 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $170.79 | 13.3% | 8 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $162.57 | 12.7% | 8 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $118.71 | 9.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $106.55 | 8.3% | 5 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $104.52 | 8.2% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $100.97 | 7.9% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $84.66 | 6.6% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $51.13 | 4.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.50 | 3.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.46 | 2.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.05 | 2.6% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $24.56 | 1.9% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.82 | 1.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.46 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,280.69 | 62 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $170.79 | 8 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $162.57 | 8 | 2025 |
Source payment records
|
|||||
| Livdelzi Normalized: livdelzi |
Drug | Gilead Sciences, Inc. | $118.71 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $112.77 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $106.55 | 5 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $104.52 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $100.97 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $100.97 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $98.46 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $89.13 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $87.17 | 8 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $87.17 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $84.66 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $51.13 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $42.50 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $42.50 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $37.46 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.05 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $27.20 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $24.56 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $21.82 | 1 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $21.46 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 123 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 137 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 115 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
137 | 39 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
123 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
71 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
115 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
110 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 531 | 169 |
| Gabapentin | Gabapentin | 432 | 139 |
| Omeprazole | Omeprazole | 315 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 313 | 109 |
| Hydrochlorothiazide | Hydrochlorothiazide | 281 | 91 |
| Metformin Hcl | Metformin Hcl | 238 | 74 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 212 | 54 |
| Carvedilol | Carvedilol | 206 | 62 |
| Metformin Hcl Er | Metformin Hcl | 206 | 64 |
| Jardiance | Empagliflozin | 205 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 201 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 190 | 65 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 186 | 49 |
| Losartan Potassium | Losartan Potassium | 180 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 171 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 171 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 166 | 43 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 159 | 49 |
| Lisinopril | Lisinopril | 151 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 146 | 49 |
| Linzess | Linaclotide | 137 | 39 |
| Nifedipine Er | Nifedipine | 133 | 40 |
| Meclizine Hcl | Meclizine Hcl | 124 | 40 |
| Farxiga | Dapagliflozin Propanediol | 123 | 22 |
| Ozempic | Semaglutide | 115 | 19 |
| Eliquis | Apixaban | 110 | 29 |
| Trulicity | Dulaglutide | 109 | 20 |
| Famotidine | Famotidine | 108 | 40 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 107 | 39 |
| Quetiapine Fumarate | Quetiapine Fumarate | 107 | 23 |
| Mirtazapine | Mirtazapine | 104 | 26 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 101 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 101 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 98 | 33 |
| Sertraline Hcl | Sertraline Hcl | 95 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 93 | 24 |
| Alendronate Sodium | Alendronate Sodium | 92 | 29 |
| Chlorthalidone | Chlorthalidone | 91 | 28 |
| Meloxicam | Meloxicam | 90 | 41 |
| Simvastatin | Simvastatin | 83 | 26 |
| Ezetimibe | Ezetimibe | 76 | 20 |
| Ammonium Lactate | Ammonium Lactate | 72 | 22 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 72 | 27 |
| Entresto | Sacubitril/Valsartan | 71 | 17 |
| Januvia | Sitagliptin Phosphate | 70 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 68 | 15 |
| Bupropion Xl | Bupropion Hcl | 66 | 15 |
| Furosemide | Furosemide | 62 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 19 |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 56 | 17 |
| Spironolactone | Spironolactone | 55 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 17 |
| Fluocinonide | Fluocinonide | 50 | 16 |
| Atenolol | Atenolol | 47 | 11 |
| Montelukast Sodium | Montelukast Sodium | 47 | 19 |
| Donepezil Hcl | Donepezil Hcl | 43 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 12 |
| Finasteride | Finasteride | 34 | suppressed |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Novolog Flexpen | Insulin Aspart | 33 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 33 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 30 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Allopurinol | Allopurinol | 29 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 29 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 27 | suppressed |
| Clotrimazole | Clotrimazole | 27 | 15 |
| Latanoprost | Latanoprost | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 26 | suppressed |
| Nateglinide | Nateglinide | 26 | suppressed |
| Prednisone | Prednisone | 26 | 18 |
| Glimepiride | Glimepiride | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Ciclopirox | Ciclopirox | 21 | suppressed |
| Naproxen | Naproxen | 21 | 11 |
| Rybelsus | Semaglutide | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | 11 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | 11 |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Cilostazol | Cilostazol | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | 13 |
| Lorazepam | Lorazepam | 18 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 18 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Dulera | Mometasone/Formoterol | 13 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 13 | suppressed |
| Procto-Med Hc | Hydrocortisone | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Tivicay | Dolutegravir Sodium | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,280.69 · 62 records | ABBVIE INC. | ABRYSVO, CAPLYTA, CAPVAXIVE, COMIRNATY, COSENTYX, CREON, Cologuard Collection Kit, FARXIGA, IBSRELA, Kerendia, LINZESS, Livdelzi, NEXLETOL, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, TREMFYA, UBRELVY, VERQUVO, ZENPEP | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error